Search

Search Constraints

You searched for: Author/Creator Oza, Amit

Search Results

11. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma. (1st November 2014)

12. High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Issue 16 (2nd June 2019)

13. Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study. Issue 3 (11th October 2013)

14. Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study. Issue 3 (11th October 2013)

15. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2021)

16. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. Issue 2 (February 2019)

17. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Issue 1 (December 2016)

18. O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. (4th December 2022)

19. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2021)

20. Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. Issue 1 (January 2023)